MedTrace Logo

Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer

NCT03170284 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2017-05-31

No results posted yet for this study

Summary

The purpose of this study is to examine the efficacy of Bevacizumab in addition to platinum-based chemotherapy for first-line treatment of participants with advanced stage (IIIB/IV) non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Bevacizumab

Bevacizumab is prescribed by physicians as per SPC.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-17
Primary Completion
2012-08-01
Completion
2012-08-01
FDA Drug
Yes

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03170284 on ClinicalTrials.gov